Disease renaming

The OT Platform describes associations to ‘non-alcoholic fatty liver disease’ (NAFLD). The disease has been gradually substituted with ‘metabolic dysfunction-associated steatotic liver disease’ (MASLD) (such as in the journal), but the Platform seems not to include the new term. Could anyone please explain whether or how the OT Platform will update the database (e.g., replacement or co-existence of the old and new terms)?

Hi @tzukuo

Thanks for bringing it to our attention.

Open Targets Platform uses the EMBL-EBI Experimental Factor Ontology (EFO) as a scaffold for the disease or phenotype entity. Hence, it would be best if you could kindly raise this issue with the EFO team and request them to add the new disease term to their repository. The disease terms in the Open Targets Platform will get updated once it has been added to the Experimental Factor Ontology (EFO).


Many thanks for your feedback, @Prashant_Uniyal . I will bring this to my team!